Skip to Content

ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses

This article is about the findings of the CONTACT-02 study, highlighting the efficacy of cabozantinib and atezolizumab in treating metastatic castration-resistant prostate cancer (mCRPC) presented at ASCO GU 2024

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top